MedTrace Logo

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

NCT01785472 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1438

Last updated 2016-12-29

Study results available
· View outcomes & findings →

Summary

This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension

Conditions

  • Essential Hypertension

Interventions

DRUG

LCZ696

LCZ696 200 mg tablet

DRUG

Olmesartan

Olmesartan 20 mg capsule

DRUG

Placebo of LCZ696

Placebo tablet of LCZ696 200 mg once daily

DRUG

Placebo of Olmesartan

Placebo capsule of olmesartan 20 mg once daily

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • China
  • Hong Kong
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01785472 on ClinicalTrials.gov